Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, January 27, 2021
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
[ Wed, Jan 27th 2021
] - WOPRAI
Andrew Berens Maintained (AGIO) at Buy with Increased Target to $55 on, Jan 27th, 2021
Andrew Berens of SVB Leerink, Maintained "Agios Pharmaceuticals, Inc." (AGIO) at Buy with Increased Target from $51 to $55 on, Jan 27th, 2021.
Andrew has made no other calls on AGIO in the last 4 months.
There are 2 other peers that have a rating on AGIO. Out of the 2 peers that are also analyzing AGIO, 0 agree with Andrew's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Andrew
- John Newman of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $57 on, Monday, December 28th, 2020
- Peter Lawson of "Barclays" Upgraded from Hold to Buy and Held Target at $46 on, Thursday, October 22nd, 2020
